Abstract
Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.
| Original language | English (US) |
|---|---|
| Article number | e1201625 |
| Journal | OncoImmunology |
| Volume | 5 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2 2016 |
| Externally published | Yes |
Fingerprint
Keywords
- Dendritic cell vaccination
- immunotherapy
- ipilimumab
- melanoma
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
Cite this
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. / Boudewijns, Steve; Koornstra, Rutger H T; Westdorp, Harm; Schreibelt, Gerty; van den Eertwegh, Alfons J M; Geukes Foppen, Marnix H.; Haanen, John B.; de Vries, I. Jolanda M; Figdor, Carl G.; Bol, Kalijn F.; Gerritsen, Winald R.
In: OncoImmunology, Vol. 5, No. 8, e1201625, 02.08.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
AU - Boudewijns, Steve
AU - Koornstra, Rutger H T
AU - Westdorp, Harm
AU - Schreibelt, Gerty
AU - van den Eertwegh, Alfons J M
AU - Geukes Foppen, Marnix H.
AU - Haanen, John B.
AU - de Vries, I. Jolanda M
AU - Figdor, Carl G.
AU - Bol, Kalijn F.
AU - Gerritsen, Winald R.
PY - 2016/8/2
Y1 - 2016/8/2
N2 - Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.
AB - Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.
KW - Dendritic cell vaccination
KW - immunotherapy
KW - ipilimumab
KW - melanoma
UR - http://www.scopus.com/inward/record.url?scp=84981709947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981709947&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2016.1201625
DO - 10.1080/2162402X.2016.1201625
M3 - Article
VL - 5
JO - OncoImmunology
JF - OncoImmunology
SN - 2162-4011
IS - 8
M1 - e1201625
ER -